《美股業績》渤健藥廠(BIIB.US)業績預測遜預期 股價挫逾7%
美國渤健藥廠(Biogen)(BIIB.US)公布去年第四季業績。純利按年跌55%至2.5億美元,每股季度攤薄純利1.71美元,經調整後為2.95美元。公司去年同期錄得1.95億美元或有對價重估收益,現財年重組支出亦年增逾9,000萬美元,但收購資產減值按年減少近1億美元。
公司季內收入按年跌6%至23.86億美元,差於市場預期的24.7億美元。公司預期今年經調整每股盈利介乎15至16美元,中位數低於市場預期的15.65美元。
公司估計,與日本衛采聯合開發的阿茲海默症藥Leqembi,有3,800名病人已經或接近獲得處方應用,較去年底增加約56%。
渤健股價昨日(13日)跌7.4%,報226.65美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.